 Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma Immune checkpoint inhibitors (ICB) have significantly prolonged patient survival across multiple tumor types, particularly in melanoma. Interestingly, gender specific differences in response to ICB